uniQure

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The stock price of Uniqure NV (NASDAQ: QURE) fell by over 29% today. This is why it happened.

Uniqure Stock (QURE): Why The Price Substantially Fell Today

UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130 for Huntington's disease.  AMT-130 was generally well tolerated at the lower dose of 6x1012 vector genomes (vg).

UniQure Shares Fall After Clinical Update From Huntington's Disease Gene Therapy Trial

~ Treatment was well tolerated with no significant safety issues

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

CSL Behring and uniQure N.V.'s (NASDAQ: QURE) etranacogene dezaparvovec, a hemophilia B gene therapy, achieved the pre-specified primary endpoint of non-inferiority in annualized bleeding rate (ABR) compared to baseline Factor IX (FIX) prophylactic treatment.

CSL Behring, UniQure's Hemophilia B Gene Therapy Hits Primary Endpoint

~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec ~

uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B

QURE is a leader in gene therapy, and has the first commercially licensed gene therapy manufacturing facility. Utilizing their industry leading technology, they are developing treatments and cures for genetic diseases (e.g., Huntington's and hemophilia B).

UniQure: Leading Gene Therapy Company

The recent rise can be attributed to its Q3 loss of $0.79 per share, which was better than the consensus estimate of $1.05 loss per share.

What's Next For UniQure Stock After A 10% Rise In A Month?

~ No Significant Safety Concerns Observed in First Four Patients Enrolled in Higher-dose Cohort ~

uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease

LEXINGTON, Mass. and AMSTERDAM, Nov. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

uniQure to Participate in Upcoming Industry Conferences in November

~ Completed 78-week follow-up for hemophilia B pivotal study, with top-line data expected by year-end 2021 ~

uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress

Biotech Executive Brings Extensive Experience Developing Advanced Therapies and Regenerative Medicines Biotech Executive Brings Extensive Experience Developing Advanced Therapies and Regenerative Medicines

uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors

UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will uniQure (QURE) Report Negative Q3 Earnings? What You Should Know

Oral Presentation to Highlight AMT-191 for Fabry Disease Oral Presentation to Highlight AMT-191 for Fabry Disease

uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

uniQure to Participate in Multiple Upcoming Industry Conferences in October

Robert Gut, Director at Uniqure (NASDAQ:QURE), made a large insider sell on September 21, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Gut sold 4,500 shares of Uniqure at a price of $36.61.

Director Of Uniqure Sold $164.75 Thousand In Stock

MeiraGTx Holdings plc

Solid Biosciences

Sarepta Therapeutics

Voyager Therapeutics

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

Match Group

Tandem Diabetes Care

This Simple Thing Sent These 3 Nasdaq Stocks Soaring Tuesday

LEXINGTON, Mass. and AMSTERDAM, Sept. 07, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

uniQure to Participate in Multiple Upcoming Industry Conferences in September

~ No Significant Safety Concerns Observed Across a Total of 14 Completed Procedures ~

uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease

uniQure (QURE) delivered earnings and revenue surprises of 198.60% and 118.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

UniQure (QURE) Q2 Earnings and Revenues Top Estimates

~ Expanded gene therapy pipeline with four new research programs and announced acquisition of Corlieve Therapeutics ~

uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

UniQure (QURE) to Report Q2 Results: Wall Street Expects Earnings Growth

Biogen

Novartis

Pfizer

Roche Holding AG

SAGE Therapeutics

Several drugmakers have important clinical trial updates on the way.

Late-Stage Clinical Study Readouts Biotech Investors Should Watch

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations, of which three are oral presentations, will be delivered at the International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress being held July 17-21, 2021.

uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress

The stock price of uniQure stock, a gene therapy company, has seen a a large 13% drop over the last five trading days. The company recently announced that the U.S. FDA has asked for eighteen months of data for its hemophilia B gene therapy, implying a six month delay in filing for accelerated.

What's Next For uniQure Stock After A 13% Drop Last Week?

News for uniQure Stock (QURE)